Episode
Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
- Podcast
- Hematologic Oncology Update
- Published
- Jul 9, 2026
- Duration seconds
- 7034
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/novel-therapies-for-non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hematologic-oncology-update-916423/novel-therapies-for-non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics: Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00) Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41) Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23) Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48) CME information and select publications